​

Funding Round

Series E - ENTEROME

Series E - ENTEROME

Investment Firm

Overview

Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.

Announced Date

Jun 25, 2020

Funding Type

Series E

Highlights

Location

Europe

Social

Investor Lead

N/A

Participant Investors

5

Investor Name
Participant InvestorPrincipia SGR
Participant InvestorNestlé Health Science
Participant InvestorTakeda
Participant InvestorOmnes Capital
Participant InvestorSeventure Partners

Round Details and Background

ENTEROME raised $51939777 on 2020-06-25 in Series E

Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.

Company Funding History

9

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Oct 30, 2023
Venture Round - ENTEROME
1-3.2M
Apr 20, 2016
Series C - ENTEROME
5-16.4M
May 01, 2014
Series B - ENTEROME
3-15.3M
Mar 23, 2012
Series A - ENTEROME
4-9.9M

Recent Activity

There is no recent news or activity for this profile.